By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Research & Development  

1400 McKean Road

Spring House  Pennsylvania  19477  U.S.A.
Phone: 858-450-2000 Fax: n/a


At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.

As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.


Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.

Key Statistics

Ownership: Private

Web Site: Janssen R&D


Company News
Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy 4/4/2017 7:34:54 AM
Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin's Lymphoma 12/6/2016 6:49:24 AM
Janssen R&D Partners With University of Pennsylvania And Castleman Disease Collaborative Network To Launch First Global Patient Registry For Castleman Disease 10/27/2016 7:31:48 AM
Johnson & Johnson Innovation (JNJ) And Janssen R&D Launch World Without Disease QuickFire Challenge 6/6/2016 12:46:08 PM
Janssen R&D To Present Data From Six Compounds Including Daratumumab And Ibrutinib At The 2016 ASCO Annual Meeting 5/19/2016 6:55:51 AM
Medivir (MVRBF) Announces That Janssen R&D Decided To Start A Phase IIb Study Of Combinations Of Simeprevir, Odalasvir And AL-335 For The Treatment Of Hepatitis C 5/11/2016 11:00:59 AM
Janssen Research & Development To Showcase Growing Portfolio With More Than 40 Data Presentations At The 2015 American Society of Hematology Annual Meeting 11/5/2015 9:25:16 AM
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent 10/28/2015 12:46:43 PM
Janssen Research & Development Release:Phase 3 Data Show STELARA Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn's Disease 10/19/2015 8:05:42 AM
U.S. FDA Grants Priority Review To Janssen Research & Development For Daratumumab As A Treatment For Multiple Myeloma 9/8/2015 6:34:43 AM